← Leaderboards
Jennifer Elynn Yeh
Harvard Medical School
$162,017
Attributed
$162,017
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $48.1K · FY2013–16$50K$37.5K$25K$12.5K$0
'13
'14
'15
'16
Funding mix
By agency
NIH$162,017 · 1
By mechanism
F30$162,017 · 1
Top collaborators
No co-investigators on record.
Most similar at Harvard Medical School
Same institution · by research overlap
- Andrew Bruce Lassar$15,065,323
- Nathalie Yr Agar$10,055,254
- Christopher S Chen$23,331,537
- Jessica L Whited$7,872,256
- Arlene H Sharpe$68,359,602
Others in their field
Top investigators on “Cytotoxic”
- David Heimbrook · Leidos Biomedical Research, Inc.$60,494,681
- Philip J Disaia · University Of California Irvine$58,213,103
- Kent J. Weinhold · Duke University$45,381,151
- Brenda J. Weigel · University Of Minnesota$36,792,183
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$34,242,475
- Douglas F Nixon · J. David Gladstone Institutes$30,748,895
Research focus
CytotoxicApoptosisApoptoticAcetylationAutomobile DrivingBinding SitesBiologyBreast Cancer CellAttentionAmericanCancer DiagnosisCancer EtiologyCd44 GeneCell ProliferationCellsCell SurfaceCell SurvivalCessation Of LifeChemotherapeutic AgentChemotherapyChromatin ImmunoprecipitationClassificationCombined Modality TherapyDesign
Grant awards (4)
Defining the CD44-STAT3 axis in the pathogenesis of triple-negative breast cancer$44,680
F30 · FY2016 · CA · contact PI
Defining the CD44-STAT3 axis in the pathogenesis of triple-negative breast cancer$48,120
F30 · FY2015 · CA · contact PI
Defining the CD44-STAT3 axis in the pathogenesis of triple-negative breast cancer$35,029
F30 · FY2014 · CA · contact PI
Defining the CD44-STAT3 axis in the pathogenesis of triple-negative breast cancer$34,188
F30 · FY2013 · CA · contact PI